With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
We collected publicly available information, interviewed experts, and used our diverse range of expertise to analyse and model the COVID-19 vaccine portfolio. There is significant uncertainty surrounding the development, approval and manufacturing of COVID-19 vaccines. We find that the chances of developing a safe and efficacious vaccine are high but it will not occur in the immediate future, and it is unlikely to be the silver bullet that resolves the pandemic and returns our world to normal. Using inputs generated from expert interviews, our modelling suggests that there is a 50 percent chance that by the end of April 2021 there will be a vaccine safe and efficacious enough to win approval from a stringent regulator; by the end of 2021, this rises to 85 percent. Inputs more optimistic or pessimistic than those we gained through expert interviews lead to very different results.
We also modelled how long it would take to manufacture COVID-19 vaccines once they are approved. Our modelling suggests that it will probably take more than a year to produce enough vaccines to inoculate the world’s 50 million medical staff, and that it could be September 2023 before we have enough doses for the whole world. It is not clear that these early vaccines will be efficacious enough to end the COVID-19 crisis. The vast majority of experts we spoke with predict that first-generation vaccines will not be effective enough to end the pandemic on their own, and that it will take longer to develop vaccines that fully prevent infection. This means that the world must be prepared to commit to other public health measures to control the spread of the virus for years, and should invest in a wider, more diversified portfolio of vaccines through better international collaboration and market incentives, as well as focus on diagnostics and treatments. All this while carefully managing the collateral damage from the ongoing policy response.